Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia

Journal of Neuroimmunology

Volumn 269, Issue 1-2, 2014, Pages 68-75

  Jones, Amanda L ^a   Mowry, Bryan J ^b   McLean, Duncan E ^b   Mantzioris, Basil X ^b   Pender, Michael P ^b,c   Greer, Judith M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Autoantibodies; Immunohistochemistry; M1 muscarinic acetylcholine receptor; Neurofilament medium (NFM); Schizophrenia

Indexed keywords

AUTOANTIBODY; MUSCARINIC M1 RECEPTOR; NEUROFILAMENT M PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PERIKARYON; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCHIZOPHRENIA;

AUTOANTIBODIES; IMMUNOHISTOCHEMISTRY; M1 MUSCARINIC ACETYLCHOLINE RECEPTOR; NEUROFILAMENT MEDIUM (NFM); SCHIZOPHRENIA;

ADULT; AGED; AMINO ACID SEQUENCE; AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEUROFILAMENT PROTEINS; PREFRONTAL CORTEX; RECEPTOR, MUSCARINIC M1; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84896391311     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.02.008     Document Type: Article

References (56)

1. Aghajanian G.K., Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Brain Res. Rev. 2000, 31:302-312.
2. American Psychiatric Association Task Force on DSM-IV Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR xxxvii 2000, (943 pp.).
3. Bartos A., Fialova L., Soukupova J., Kukal J., Malbohan I., Pit'ha J. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J. Neurol. 2007, 254:20-25.
4. Ben-Shachar D., Livne E., Spanier I., Leenders K.L., Youdim M.B. Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake. J. Neurochem. 1994, 62:1112-1118.
5. Bergson C., Levenson R., Goldman-Rakic P.S., Lidow M.S. Dopamine receptor-interacting proteins: the Ca2+ connection in dopamine signaling. Trends Pharmacol. Sci. 2003, 24:486-492.
6. Bessler H., Levental Z., Karp L., Modai I., Djaldetti M., Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol. Psychiatry 1995, 38:297-302.
7. Borda T., Perez Rivera R., Joensen L., Gomez R.M., Sterin-Borda L. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J. Immunol. 2002, 168:3667-3674.
8. Borda T., Gomez R., Berria M.I., Sterin-Borda L. Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera. Glia 2004, 45:144-154.
9. Clinton S.M., Abelson S., Haroutunian V., Davis K., Meador-Woodruff J.H. Neurofilament subunit protein abnormalities in the thalamus in schizophrenia. Thalamus Relat. Syst. 2004, 2:265-272.
10. Dean B. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia. Curr. Pharm. Biotechnol. 2012, 13:1563-1571.
11. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 2001, 7:1189-1193.
12. Dolan R.J., Fletcher P.F. Encoding and retrieval in human medial temporal lobes: an empirical investigation using functional magnetic resonance imaging (fMRI). Hippocampus 1999, 9:25-34.
13. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun. 2006, 20:532-545.
14. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?. J. Psychiatr. Res. 1982, 17:319-334.
15. Garbutt J.C., van Kammen D.P. The interaction between GABA and dopamine: implications for schizophrenia. Schizophr. Bull. 1983, 9:336-353.
16. Goghari V.M., Sponheim S.R., MacDonald A.W. The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci. Biobehav. Rev. 2010, 34:468-486.
17. Heath R.G., McCarron K.L., O'Neil C.E. Antiseptal brain antibody in IgG of schizophrenic patients. Biol. Psychiatry 1989, 25:725-733.
18. Heckers S., Weiss A.P., Alpert N.M., Schacter D.L. Hippocampal and brain stem activation during word retrieval after repeated and semantic encoding. Cereb. Cortex 2002, 12:900-907.
19. Henneberg A.E., Horter S., Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr. Res. 1994, 14:15-22.
20. Jones P., Cannon M. The new epidemiology of schizophrenia. Psychiatr. Clin. N. Am. 1998, 21:1-25.
21. Jones A.L., Mowry B.J., Pender M.P., Greer J.M. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?. Immunol. Cell Biol. 2005, 83:9-17.
22. Kim O.J., Ariano M.A., Lazzarini R.A., Levine M.S., Sibley D.R. Neurofilament-M interacts with the D1 dopamine receptor to regulate cell surface expression and desensitization. J. Neurosci. 2002, 22:5920-5930.
23. Knight J.G., Knight A., Menkes D.B., Mullen P.E. Autoantibodies against brain septal region antigens specific to unmedicated schizophrenia? Biol. Psychiatry 1990, 28:467-474.
24. Kowalski J., Blada P., Kucia K., Madej A., Herman Z.S. Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr. Res. 2001, 50:169-175.
25. Lennox B.R., Coles A.J., Vincent A. Antibody-mediated encephalitis: a treatable cause of schizophrenia. Brit. J. Psychiatry 2012, 200:92-94.
26. Logan D.G., Deodnar S.D. Schizophrenia, an immunologic disorder?. JAMA 1970, 212:1703-1704.
27. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G.J., Pioli R., Boin F., Kenis G., Bosmans E., de Jongh R., Altamura C.A. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res. 2002, 54:281-291.
28. Martins-de-Souza D., Gattaz W.F., Schmitt A., Maccarrone G., Hunyadi-Gulyas E., Eberlin M.N., Souza G.H., Marangoni S., Novello J.C., Turck C.W., Dias-Neto E. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J. Psychiatr. Res. 2009, 43:978-986.
29. Moehle M.S., Luduena R.F., Haroutunian V., Meador-Woodruff J.H., McCullumsmith R.E. Regional differences in expression of β-tubulin isoforms in schizophrenia. Schizophr. Res. 2012, 135:181-186.
30. Mowry B.J., Gratten J. The emerging spectrum of allelic variation in schizophrenia: current evidence and strategies for the identification and functional characterization of common and rare variants. Mol. Psychiatry 2013, 18:38-52.
31. Mukherjee S., Mahadik S.P., Korenovsky A., Laev H., Schnur D.B., Reddy R. Serum antibodies to nicotinic acetylcholine receptors in schizophrenic patients. Schizophr. Res. 1994, 12:131-136.
32. Muller N., Hofschuster E., Ackenheil M., Eckstein R. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatr. Scand. 1993, 87:66-71.
33. Murray R.M., Jones P., O'Callaghan E. Fetal brain development and later schizophrenia. Ciba Found. Symp. 1991, 156:155-163.
34. Pelonero A.L., Pandurangi A.K., Calabrese V.P. Autoantibodies to brain lipids in schizophrenia. Am. J. Psychiatry 1990, 147:661-662.
35. Pennington K., Beasley C.L., Dicker P., Fagan A., English J., Pariante C.M., Wait R., Dunn M.J., Cotter D.R. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol. Psychiatry 2008, 13:1102-1117.
36. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
37. Rhoads J., Guirgis H., McKnight C., Duchemin A.-M. Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia. Schizophr. Res. 2011, 129:213-214.
38. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005, 2:e141.
39. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987, 1:133-152.
40. Shima S., Yano K., Sugiura M., Tokunaga Y. Anticerebral antibodies in functional psychoses. Biol. Psychiatry 1991, 29:322-328.
41. Sivagnanasundaram S., Crossett B., Dedova I., Cordwell S., Matsumoto I. Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study. Proteomics Clin. Appl. 2007, 1:1291-1305.
42. Stevens A., Weller M. Ganglioside antibodies in schizophrenia and major depression. Biol. Psychiatry 1992, 32:728-730.
43. Strous R.D., Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J. Autoimmun. 2006, 27:71-80.
44. Strous R.D., Greenbaum L., Kanyas K., Merbl Y., Horowitz A., Karni O., Viglin D., Olender T., Deshpande S.N., Lancet D., Ben-Asher E., Lerer B. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. Int. J. Neuropsychopharmacol. 2007, 10:321-333.
45. Tanaka S., Matsunaga H., Kimura M., Tatsumi K., Hidaka Y., Takano T., Uema T., Takeda M., Amino N. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J. Neuroimmunol. 2003, 141:155-164.
46. Teplizki H.A., Sela B., Shoenfeld Y. Autoantibodies to brain and polynucleotides in patients with schizophrenia: a puzzle. Immunol. Res. 1992, 11:66-73.
47. Tsutsui K., Kanbayashi T., Tanaka K., Boku S., Ito W., Tokunaga J., Mori A., Hishikawa Y., Shimizu T., Nishino S. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012, 12:37.
48. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
49. von Kirchbach A., Fischer E.G., Kornhuber H.H. Failure to detect dopamine receptor IgG autoantibodies in sera of schizophrenic patients. Short note. J. Neural Transm. 1987, 70:175-179.
50. Wandinger K.P., Saschenbrecker S., Stoecker W., Dalmau J. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J. Neuroimmunol. 2011, 231:86-91.
51. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 1987, 44:660-669.
52. Whittingham S., Mackay I.R., Jones I.H., Davies B. Absence of brain antibodies in patients with schizophrenia. BMJ 1968, 1:347-348.
53. Yang Z.W., Chengappa K.N., Shurin G., Brar J.S., Rabin B.S., Gubbi A.V., Ganguli R. An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia. Psychol. Med. 1994, 24:449-455.
54. Yolken R.H., Torrey E.F. Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 1995, 8:131-145.
55. Zandi M.S., Irani S.R., Lang B., Waters P., Jones P.B., McKenna P., Coles A.J., Vincent A., Lennox B.R. Disease-relevant autoantibodies in first episode schizophrenia. J. Neurol. 2011, 258:686-688.
56. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry 2004, 65:940-947.